Keyphrases
Selective Androgen Receptor Modulator
100%
Androgen Receptor
91%
AR-42
54%
Androgens
51%
Estrogen Receptor
47%
Pharmacokinetics
46%
Histone Deacetylase Inhibitor (HDACi)
44%
Estrogen Receptor Agonists
38%
Dihydrotestosterone
36%
Cancer Cachexia
33%
Immune Checkpoint Inhibitors
29%
Androgen Receptor Antagonist
28%
Tissue Selectivity
28%
Acute Myeloid Leukemia
27%
Steroidal
27%
Selective Estrogen Receptor Modulators
27%
Cachexia
25%
Enobosarm
25%
Inflammation
25%
Hepatocellular Carcinoma
24%
Prostate
23%
Signaling Pathway
21%
Anabolic Steroids
20%
Multiple Myeloma
20%
Natural Products
20%
Mechanism of Action
20%
Muscle Wasting
20%
Growth Factors
20%
Androgen Therapy
20%
Androgen Deprivation Therapy
19%
Non-steroidal
19%
Estrogen Receptor Gene
19%
Pharmacologic
19%
Receptor Function
19%
Molecular Targets
18%
Tumor
18%
Insulin-like
18%
Non-canonical Pathway
18%
Estrogenic Activity
18%
Androgen Receptor Splice Variant
17%
Molecular Mechanism
17%
Cancer Patients
17%
Testosterone
17%
Pancreatic Ductal Adenocarcinoma
16%
Tyrosine Kinase Inhibitor
16%
Phase 1 Trial
16%
Structure-activity Relationship
16%
Nonsteroidal Estrogens
16%
Myeloma Cells
16%
Genomic Signals
16%
Pharmacology, Toxicology and Pharmaceutical Science
Selective Androgen Receptor Modulator
83%
Androgen Receptor
77%
Androgen
70%
Pharmacokinetics
66%
Estrogen Receptor
64%
Malignant Neoplasm
56%
Neoplasm
52%
Receptor Agonist
38%
Histone Deacetylase Inhibitor
36%
Cachexia
33%
Androstanolone
31%
Liver Cell Carcinoma
27%
Side Effect
26%
Breast Cancer
26%
Acute Myeloid Leukemia
26%
Bioavailability
25%
Multiple Myeloma
25%
Enobosarm
25%
Disease
23%
Prostate Cancer
22%
Immune Checkpoint Inhibitor
20%
Tamoxifen
20%
Pancreas Adenocarcinoma
20%
Androgen Receptor Antagonist
18%
Molecular Target
18%
Solid Malignant Neoplasm
17%
Pancreas Cancer
16%
Ovary Cancer
16%
Muscle Atrophy
16%
Estrogens
16%
Anabolic Steroid
16%
Nandrolone
16%
Somatomedin C Receptor
16%
Cytochrome P450
16%
Progestin
16%
Rifampicin
16%
Bolandiol
16%
Itraconazole
16%
Drug Interaction
16%
Toremifene
16%
Rosuvastatin
16%
Probenecid
16%
Celecoxib
16%
Inflammation
16%
Receptor Subtype
16%
Tolerability
15%
Receptor
15%
Clinical Trial
13%
Immunotherapy
12%
Myeloma
12%
Medicine and Dentistry
Selective Androgen Receptor Modulator
41%
Androgen Receptor
38%
Estrogen Receptor
35%
Cachexia
33%
Androgen
26%
Histone Deacetylase Inhibitor
25%
Breast Cancer
22%
Pancreas Adenocarcinoma
20%
Disease
19%
Malignant Neoplasm
19%
Hepatocellular Carcinoma
18%
Neoplasm
18%
Androgen Therapy
18%
Immunocompetent Cell
16%
Pancreas Cancer
16%
Estrogens
16%
Muscle Atrophy
15%
Receptor Subtype
14%
Side Effect
12%
Xenograft
11%
Cancer
11%
In Vitro
10%
Hormone Therapy
10%
Prostate Cancer
10%
Androstanolone
10%
Osteolysis
10%
B-Cell Lymphoma
9%
Programmed Cell Death
9%
Fc Receptor
8%
Multiple Myeloma
8%
Diethylnitrosamine
8%
Tyrosine-Kinase Inhibitor
8%
Autophagy
8%
DNA Repair
8%
Immune-Related Adverse Events
8%
B Cell
8%
Acute Myeloid Leukemia
8%
Bruton Tyrosine Kinase
8%
Lung Cancer
8%
Cell Penetrating Peptide
8%
Neurofibromatosis Type II
8%
SIRT6
8%
T-Cell Lymphoma
8%
Experimental Neoplasm
8%
Nicotinamide Phosphoribosyltransferase
8%
Chronic Pancreatitis
8%
Acalabrutinib
8%
Fatty Acid
8%
Histone Deacetylase 8
8%
Non Small Cell Lung Cancer
8%
